Medigene AG (LON: 0QGJ)

Market Cap	16.80M
Revenue (ttm)	6.31M
Net Income (ttm)	-13.51M
Shares Out	n/a
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26
Average Volume	113
Open	1.250
Previous Close	1.312
Day's Range	1.250 - 1.250
52-Week Range	1.250 - 2.250
Beta	0.92
RSI	54.45
Earnings Date	Mar 28, 2025

About Medigene AG

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develops MDG2011, MDG2021, MDG2012, MDG20XX, and MDG10xx to treat multiple solid tumors. It has a strategic partnership with BioNTech to develop TCRbased immu...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1994
• Employees: 76
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QGJ

Financial Performance

In 2023, Medigene AG's revenue was 6.03 million, a decrease of -80.69% compared to the previous year's 31.25 million. Losses were -16.18 million, 94.2% more than in 2022.

Financial numbers in EUR